Inositol 1,4,5-trisphosphate (IP 3 ) is a ubiquitous intracellular messenger regulating diverse functions in almost all mammalian cell types. It is generated by membrane receptors that couple to phospholipase C (PLC), an enzyme which liberates IP 3 from phosphatidylinositol 4,5-bisphosphate (PIP 2 ). The major action of IP 3 , which is hydrophilic and thus translocates from the membrane into the cytoplasm, is to induce Ca 2+ release from endogenous stores through IP 3 receptors (IP 3 Rs). Cardiac excitation-contraction coupling relies largely on ryanodine receptor (RyR)-induced Ca 2+ release from the sarcoplasmic reticulum. Myocytes express a significantly larger number of RyRs compared to IP 3 Rs (~100:1), and furthermore they experience substantial fluxes of Ca 2+ with each heartbeat. Therefore, the role of IP 3 and IP 3 -mediated Ca 2+ signaling in cardiac myocytes has long been enigmatic. Recent evidence, however, indicates that despite their paucity cardiac IP 3 Rs may play crucial roles in regulating diverse cardiac functions. Strategic localization of IP 3 Rs in cytoplasmic compartments and the nucleus enables them to participate in subsarcolemmal, bulk cytoplasmic and nuclear Ca 2+ signaling in embryonic stem cell-derived and neonatal cardiomyocytes, and in adult cardiac myocytes from the atria and ventricles. Intriguingly, expression of both IP 3 Rs and membrane receptors that couple to PLC/IP 3 signaling is altered in cardiac disease such as atrial fibrillation or heart failure, suggesting the involvement of IP 3 signaling in the pathology of these diseases. Thus, IP 3 exerts important physiological and pathological functions in the heart, ranging from the regulation of pacemaking, excitation-contraction and excitation-transcription coupling to the initiation and/or progression of arrhythmias, hypertrophy and heart failure.
The discovery of IP 3
A quarter of a century ago it was shown that D-myo inositol 1,4,5-trisphosphate (IP 3 ) releases Ca 2+ from a non-mitochondrial internal Ca 2+ store [1] . Since this hallmark discovery, IP 3 has emerged as a ubiquitous intracellular messenger, releasing Ca 2+ from stores through activation of IP 3 receptors (IP 3 Rs) in almost all eukaryotic cells. The major IP 3 -sensitive intracellular Ca 2+ store is the endoplasmic reticulum. However, IP 3 has also been shown to release Ca 2+ stored in other compartments, such as the Golgi and the nuclear envelope [2] . In addition, IP 3 Rs are present on the plasma membrane of some cell types, where they can gate Ca 2+ influx [3] . A crucial role for IP release has been demonstrated in many mammalian cell types, ranging from tiny platelets, where it initiates blood clotting, to the impressive dendritic trees of cerebellar Purkinje neurons, where it is involved in the regulation of motor function. In the cardiovascular system, IP 3 -induced Ca 2+ release from the sarcoplasmic reticulum (SR) plays a key role in pharmacomechanical coupling in smooth muscle cells of the vasculature, and thus in the regulation of peripheral resistance and blood pressure. Despite being recognized as a potential messenger in cardiac myocytes nearly two decades ago, the role of IP 3 has been enigmatic. However, a number of recent reports have begun to unravel the physiological and potentially pathological actions of IP 3 within the heart. 3 : where does it come from and where does it go? IP 3 is generated by hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) through phosphoinositide-specific phospholipase C (PLC). PIP 2 is a relatively minor phospholipid (∼ 1% of total anionic phospholipids), but it is the main polyphosphoinositide in the sarcolemma. Its concentration in myocardium is in the range of 10-30 μM or 150-450 pmol/mg protein [4, 5] . PIP 2 itself serves important signaling functions, including the regulation of ion channels and transporters and the anchoring of cytoskeletal proteins at the membrane [6, 7] . Furthermore, it is the precursor of phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ), a phosphoinositide involved in cell signaling. There are at least 13 phosphoinositide-specific PLC isoforms grouped into six subfamilies: β, γ, δ, ɛ, η and ζ [8, 9] . Members of the β, γ, δ and ɛ subfamilies are expressed in cardiac myocytes. PLCs may be activated by heptahelical G protein-coupled receptors (PLCβ), receptor tyrosine kinases (PLCγ), PIP 2 and Ca 2+ (PLCδ) or Ras (PLCɛ). Consequently, many transmitters, neurohormonal factors, hormones and other stimuli (e.g. stretch) may increase IP 3 concentration and activate IP 3 -induced Ca 2+ release in cardiac myocytes downstream of PLC activation. Upon stimulation, intracellular IP 3 , or inositol phosphate concentration in general, has been shown to increase by a factor of N 12 [10] . However, it should be pointed out that most of these data were determined from assays of measuring total inositol phosphate accumulation over time (in the presence of the inositol monophosphatase inhibitor Li + ). Such measurements do not reflect the in vivo steady-state IP 3 increase, which is likely to be quite modest. Recently, the concentration of free IP 3 was estimated directly using a novel FRET-based biosensor. Following maximal stimulation of α-adrenergic and endothelin receptors, free IP 3 in cardiac myocytes increased to~30 nM [11] . While such biosensors are useful for detecting genuine increases in IP 3 concentration, they are less helpful in revealing the kinetics of IP 3 turnover, since binding of IP 3 to the probe buffers the molecule and protects it from hydrolyzing enzymes. Based on modeling studies, it was estimated that stimulation of atrial myocytes with endothelin transiently increases IP 3 concentration from a basal value of~15 nM to a maximal value of~35 nM within~400 s, after which the IP 3 level gradually declines and returns to baseline within tens of minutes [12] . A note of caution as to the quantitative results obtained with isolated myocytes is warranted though, since careful studies indicate that PIP 2 and inositol phosphate levels drop dramatically during the isolation procedure [13, 14] .
The ABC of IP
Because IP 3 is hydrophilic, it translocates from the sarcolemma to the cytoplasm upon formation from PIP 2 . The main cytoplasmic target of IP 3 is IP 3 Rs in the membrane of the ER/SR. There are three IP 3 R isoforms, denoted type 1, type 2 and type 3. Current evidence suggests that the heart expresses all three IP 3 R isoforms, although there is some inconsistency in the literature regarding their relative ratios in different cardiac cells. It has been proposed that type 1 IP 3 Rs are dominant in human atrial and rat Purkinje myocytes [15, 16] , whereas atrial and ventricular myocytes from most other animal species express predominantly type 2 IP 3 R and, to a lesser extent, type 3 IP 3 R (e.g. [17, 18] ). Overall, the majority of studies have concluded that the most prevalent IP 3 R isoform within contractile cardiomyocytes is type 2 (see Table 1 ). The few reports describing type 1 IP 3 Rs being more abundant [15, 16, 19] could indicate differences in IP 3 R expression between species, or that the probes employed lacked specificity.
The IP 3 R isoforms vary with respect to IP 3 affinity, activation and inactivation by Ca 2+ , regulation by ATP, phosphorylation and other modulatory factors (e.g. [20, 21] ). It is believed that subtle variations in the sensitivity of the three IP 3 R isoforms to such allosteric regulators can modulate the biophysical properties of the channels. Thus, depending on the expression and subcellular distribution of particular IP 3 R isoforms, cells may respond to alterations in IP 3 , Ca 2+ and other modulators quite differently. Furthermore, IP 3 Rs form macromolecular signaling complexes with other proteins including ankyrin B, chromogranin A and B, cytochrome c, ERp44, Homer, IP 3 R-binding protein released with IP 3 (IRBIT), the Na + /K + pump, protein phosphatases 1 and 2A, receptor for activated C kinase 1 (RACK1) and others (for reviews, see [22] [23] [24] ). The interaction of specific accessory proteins has been demonstrated to either positively or negatively regulate IP 3 R opening, with consequent alteration of cellular Ca 2+ signals (e.g. [25, 26] ). Although most of the data exploring IP 3 R-binding proteins has been derived from studies of neuronal IP 3 Rs, it is likely that cardiac IP 3 Rs form similar macromolecular complexes. As yet, only Ca 2+ -and calmodulin-dependent protein kinase II (CaMKII) has been identified as an accessory protein of cardiac IP 3 Rs [18] .
An intriguing aspect of IP 3 signaling is the presence of the entire phosphoinositide signaling network in the nucleus [27] . In addition, many receptors that act as signal transducers at the cell membrane are also found in the nuclear envelope (e.g. ET A and ET B receptors [28] ) where they might activate a nuclear PIP 2 -PLC-IP 3 cascade. The mechanism for stimulation of nuclear hormone receptors is not entirely clear, although it has been suggested that activated receptors can be internalized from the surface of cells and translocated to the nucleus where they engage signaling pathways. It is therefore plausible that nuclei may locally generate their own IP 3 . Alternatively, given that IP 3 Abbreviations: A, atrium; AF, atrial fibrillation; AV, atrio-ventricular; CS, conduction system; cyto, cytoplasm; EM, electron microscopy; HF, heart failure; ICC, immunocytochemistry; ID, intercalated discs; IHC, immunohistochemistry; L, left; NCX, Na + /Ca 2+ exchanger; NB, Northern blotting; n.d., not determined; NE, nuclear envelope; P, Purkinje; R, right; RT-PCR, reverse transcription or real time polymerase chain reaction; V, ventricle; WB, Western blotting.
is highly diffusible inside cells [29] , the IP 3 produced at the plasma membrane may be sufficient for activation of IP 3 Rs throughout a cell. The particular interest in cardiac nuclear IP 3 signaling derives from a number of recent studies that have demonstrated expression of IP 3 Rs within or around the nucleus in cardiac myocytes [18] , and involvement of perinuclear Ca 2+ signals in the regulation of kinases (e.g. nuclear CaMKII), transcription and nuclear pores. This concept is discussed in more detail below.
It is important to realize that the PIP 2 -PLC-IP 3 cascade is just a small part of a much larger signaling network, the inositide metabolome, which encompasses more than 80 gene products involved in the regulation of phosphatidylinositol phosphates and inositol phosphates. The inositide metabolome includes lipid kinases and phosphatases, lipases, inositol phosphate kinases and phosphatases (reviewed in [30] ). Inositol polyphosphates derived from IP 3 may be signaling molecules in their own right. In particular, IP 4 , IP 5 and IP 6 have been implicated in the regulation of nuclear functions (gene expression, chromatin remodeling, mRNA export and RNA editing). This adds to the complexity of IP 3 signaling and suggests that the potential roles of IP 3 go beyond the release of Ca 2+ from internal stores. Higher inositol polyphosphates, including IP 4 , IP 5 and IP 6 , have been detected in the heart [31] , as well as high affinity binding sites for IP 4 and IP 6 [32, 33] . However, their physiological functions in cardiac myocytes remain poorly understood.
Tools to study cardiac IP 3 signaling
Numerous tools are available to study cellular IP 3 signaling. They can be grouped into (A) methods to measure intracellular IP 3 levels, (B) pharmacological tools to manipulate IP 3 levels, IP 3 production and degradation, and the IP 3 receptor, and most recently (C) approaches that involve genetic manipulation of the intracellular IP 3 signaling cascade and the generation of transgenic animals with an altered IP 3 second messenger system.
(A) Of great interest for many years has been the quantitative determination of intracellular IP 3 levels. Until very recently, the real-time study of IP 3 formation, concentration dynamics and spatial distribution at the level of single living cells has not been possible. Instead, measurements have relied upon destructive methodologies [34] [35] [36] [37] . These assays essentially rely on whole cell extracts for mass analysis by competition binding, gas chromatography/mass spectrometry and ion exchange chromatography, or metabolic measurements of radio-labeled IP 3 precursors and degradation products. While these methods have generated important insights into cellular IP 3 dynamics, they are rather limited in deciphering the spatiotemporal organization of the IP 3 second messenger system at the cellular and subcellular level. Recent developments, however, have seen the arrival of novel fluorescent probes to study intracellular IP 3 dynamics. For example, a biosensor derived from the IP 3 binding domain of type-3 IP 3 R, termed 'LIBRA', was employed to measure IP 3 concentrations in living cells [38] . Similarly, the intracellular translocation of a pleckstrin homology domain from phospholipase C ∂1 fused to GFP was used to estimate [IP 3 ] [39] , and to measure agonist-induced oscillatory changes of IP 3 concentration [40] . A recent study reported the construction and characterization of prototypic fluorescent biosensors that allow quantitative measurements of cellular IP 3 levels in a living cell with temporal and spatial resolution [11] . These sensors (termed FIRE-1 and -3, for 'Fluorescent IP 3 Responsive Element' type-1 and -3) utilized the IP 3 R type-1 and type-3 ligand-binding domains expressed as chimeras terminally linked to CFP and YFP, and which could be used as FRET indicators of IP 3 . These constructs have been successfully employed to measure [IP 3 ] in neonatal and adult ventricular myocytes with high temporal and subcellular spatial resolution. For example, in FIRE-1-expressing ventricular myocytes, the agonists endothelin-1, phenylephrine and angiotensin II all produced rapid and spatially resolved increases of IP 3 concentration, with free IP 3 levels rising to 30 nM. A point source of IP 3 , experimentally achieved by membrane rupture with a patch pipette containing IP 3 , allowed detailed spatiotemporal monitoring of intracellular IP 3 diffusion, revealing that IP 3 diffusion into the nucleus occurred with a delay, and that the elevation of nuclear IP 3 concentration had a blunted rise compared to that in the cytoplasm. Furthermore, stimulation with endothelin-1 (100 nM) caused [IP 3 ] to rise more rapidly and to higher levels in the cytoplasm as compared with the nucleus. Average data indicate that the amplitude of rise in nuclear [IP 3 ] was 70 ± 9% of that in the cytoplasm, and the t 1⁄2 was about twice as long (1.3 min vs. 0.7 min) [11] . Clearly, these new biosensors are exciting and promising novel tools to study IP 3 dynamics at high temporal and spatial resolution in intact living cells, although their potential to buffer IP 3 has to be taken into account.
(B) More conventional, but nonetheless invaluable tools for the study of IP 3 signaling are pharmacological agents that interfere with the IP 3 signaling cascade. Some commonly used reagents are blockers of IP 3 formation (e.g. the PLC inhibitor U73122 and its negative control U73343), or antagonists of the IP 3 receptor (e.g. heparin, 2 aminoethoxydiphenyl borate (2-APB), xestospongins, curcumin). Like many pharmacological inhibitors, these tools all suffer from variable degrees of specificity, have numerous intracellular targets and unwanted side effects or lack membrane permeability (for discussion see [41] [42] [43] ). Recently developed membrane-permeable forms of IP 3 R agonists [44] and IP 3 species that can be activated photolytically [45, 46] have further expanded the repertoire of tools for studying IP 3 signaling.
(C) Molecular technologies are also beginning to be employed to explore cardiac IP 3 function. In particular, the generation of animals or cells with genetically altered IP 3 signaling pathways, and the development of transgenic animals. Due to the inherent nature of the rapid developments in this field, we will limit our review to two exemplary reports. The adenoviral-mediated expression of an IP 3 affinity trap (which consisted of the ligand-binding domain of the rat type-1 IP 3 R; also known as an 'IP 3 sponge') has been successfully used to abolish IP 3 -evoked effects on Ca 2+ signaling in rabbit ventricular myocytes [41] . The IP 3 sponge represents an experimental tool that can complement or replace pharmacological IP 3 R blockers, and specifically attenuate IP 3 signaling. Potentially even better than the IP 3 sponge would be the introduction of an IP 3 metabolizing enzyme (e.g. the IP 3 5' phosphatase), which does not necessarily have to be present at 1:1 stoichiometry to completely clamp IP 3 signaling. With respect to transgenic animals, it has been shown that the positive inotropic and pro-arrhythmic effects of endothelin-1 were completely abolished in mouse atrial cells lacking the IP 3 R type-2 isoform [17] . This loss of response to endothlelin-1 was specifically coupled to the absence of IP 3 Rs, since the myocytes retained a normal positive inotropic response to β-adrenergic stimulation.
4. The dilemma of cardiac IP 3 receptors: lost in an ocean of ryanodine receptors
The evidence for IP 3 2+ release channel in cardiac myocytes, is large, amounting to~500-1000 fmol/mg total protein in ventricular myocytes from various mammalian species [52] . This converts to~1.5-3.5 million RyRs in a typical~30 pl ventricular myocyte [53] . Direct comparison of the expression of RyRs and IP 3 Rs in ventricular myocytes revealed that RyRs outnumber IP 3 Rs by a factor between 50:1 and 100:1 [54] . Microsomal preparations from hearts of various species, including human, exhibit a much larger density of RyRs than IP 3 Rs. For example, RyR densities amounted tõ 3-4 pmol/mg protein in human ventricle [55, 56] and to~5.5-7 pmol/mg protein in dog, mouse, rabbit and rat ventricle [56] . IP 3 R densities, on the other hand, were~0.09 pmol/mg protein in bovine ventricle [16] , 0.66 pmol/mg protein in canine ventricle [32] , 0.46 pmol/mg protein in ferret ventricle [57] and 0.35 pmol/mg protein in rat ventricle [58] . Thus, on average there appear to be~5-80 times less IP 3 [65, 66] . For example, when RyR2 open probability is increased selectively (through application of low concentrations of caffeine), global Ca 2+ transients are enhanced at first, but then decline to reach steady-state amplitudes that are identical to the pre-caffeine amplitudes [67] . This is because some of the extra Ca 2+ released from the SR is exported from the cell through sarcolemmal mechanisms (i.e. largely NCX), which reduces SR [17, 70] and alter the kinetics of the cytoplasmic Ca 2+ transient with a prolongation of the rising phase and an acceleration of the decay [72] . Clearly, future studies should aim at analyzing IP 3 effects on cellular Ca 2+ fluxes in a more quantitative way, which will help gain more insight into the actions of IP 3 on cellular Ca 2+ homeostasis.
Elementary IP 3 -induced Ca 2+ release events in cardiac myocytes
Discrete, non-propagating elementary Ca 2+ release events have been characterized in a variety of excitable and nonexcitable cell types (for reviews see [73, 74] release. A recent report showed that this problem could be circumvented experimentally by eliminating Ca 2+ release via RyRs pharmacologically [70] . This is illustrated in Fig. 1 signals may have distinct functions of their own due to spatial separation from the machinery underlying excitation-contraction coupling. These possibilities are discussed further below.
IP 3 signaling in cardiac development
The heart is one of the first organs to develop in a growing embryo. As the heart is formed, its cells acquire the abilities to generate pulsatile Ca 2+ signals, to become electrically active and to contract. A number of studies, using either pre-natal cardiac cells or embryonic stem cell-derived myocytes, have indicated that IP 3 Rs may play a significant role in the development of the heart by contributing to the initiation of pacemaking activity, and thereby promote cardiogenesis. Spontaneous Ca 2+ oscillations begin as soon as the heart tube is created. These Ca 2+ signals are necessary to drive contraction, as well as appropriate gene transcription and structural arrangement of the nascent cardiomyocytes [85] . Indeed, inhibition of the Ca 2+ oscillations or buffering the Ca 2+ changes prevents development of the heart [86] .
As described above, type 2 RyRs underlie the release of Ca 2+ during systole in adult and neonatal cells. Mice lacking type 2 RyRs die as embryos around E10 with major cardiac defects [87] because the excitation-contraction coupling system cannot mature. However, repetitive Ca 2+ signals and rhythmic contractions occur in these RyR-deficient animals at E7-9.5 [87, 88] . In addition, the Ca 2+ signals in young embryonic heart cells are insensitive to experimental maneuvers that inhibit voltageactivated Ca 2+ channels or Na + /Ca 2+ exchange, but are affected by agents that deplete intracellular Ca 2+ stores [89] (but see [90] for an alternative view). Taken together, these data indicate that periodic Ca 2+ release from intracellular stores occurs in young embryonic heart cells, and that the channels involved are not RyRs.
There is accumulating evidence that IP 3 Rs may be responsible for the early cycling of Ca 2+ in developing myocytes prior to the maturation of excitation-contraction coupling. For example, the spontaneous Ca 2+ oscillations in murine embryonic cells were sensitive to application of 2-APB (an IP 3 R antagonist [42] ) [89] . Furthermore, IP 3 Rs are expressed in the inner mass of embryos at E5.5, and are clearly evident within the developing heart tube at E8.5 [91] . In contrast, RyRs are not abundant until E8.5 or later [91] . These data indicate that IP 3 Rs are expressed earlier than RyRs in the developing heart, and the timing of their expression correlates closely with the on-set of Ca 2+ oscillations. Stem cell-derived myocytes grown in vitro can recapitulate the development and differentiation of cardiomyocytes very closely [92] [93] [94] . The accessibility of these cells and the relative ease by which they can be genetically manipulated (compared to myocytes in early embryos) has led them to be used for many studies of cardiac development. It is established that these cells express IP 3 Rs when they are in either a proliferative state or during differentiation into cardiomyocytes [95] . Similar to their in vivo counterparts, stem cell-derived myocytes start to show spontaneous Ca 2+ oscillations, membrane depolarizations and contractions long before the cells have terminally differentiated. The mechanism underlying the acquisition of spontaneous activity in these cells is not fully clear. Likely candidates could be the hyperpolarization-activated cyclic nucleotide-gated cation (HCN) channels that are responsible for pacemaking currents (I f ) in adult tissue [96] . However, the spontaneous Ca 2+ oscillations appear to precede the appearance of substantial HCN-mediated currents, and the activity persists in the presence of I f inhibitors [97] . Furthermore, repetitive Ca 2+ transients could still be observed in cells that were fully depolarized (using K + application), thereby precluding the involvement of membrane potential oscillations [98] . In contrast, transfection of early stem cell-derived myocytes with antisense cDNA to reduce expression of type 1 IP 3 Rs, or application of an IP 3 R antagonist, significantly reduced the spontaneous beating [92, 97] . The effect of antagonizing IP 3 Rs diminishes over time [99] , suggesting that IP 3 -driven signals progressively give way to other mechanisms that generate Ca 2+ oscillations [100] . As expected of a pacemaking messenger, stimulating IP 3 production in stem cell-derived myocytes using hormonal agonists had a positive chronotropic effect, which was antagonized by either IP 3 R or phospholipase C inhibitors [101] . 3 , has directly demonstrated the presence of active IP 3 Rs in situ within neonatal myocytes [102, 103] . Furthermore, neonatal cardiac myocytes respond to several agonists (e.g. endothelin-1, angiotensin II, phenylephrine, ATP, prostaglandins, IGF-1) with IP 3 production and Ca 2+ mobilization [102, 104] . These same agonists also promote hypertrophic growth of neonatal cardiac myocytes [104, 105] . Studies using immunostaining, Western blotting and analysis of mRNA have suggested that IP 3 R types 1, 2 and 3 are expressed in neonatal cells [102, 103, 106] .
A consistent message from the investigations of neonatal myocytes is that IP 3 causes perinuclear Ca 2+ release. Almost all studies that examined either the distribution of IP 3 Rs, or the spatial pattern of IP 3 -evoked Ca 2+ signals, have reported that the channels are largely expressed in close proximity to the nucleus in neonatal cells [102, 103, [106] [107] [108] . This is unlike RyRs, which have a more widespread expression pattern in neonatal cells [102] . The perinuclear release of IP 3 -sensitive Ca 2+ stores can impact specifically on nucleoplasmic Ca 2+ levels [103] and thereby promote hypertrophic gene transcription [109] .
The overall picture that emerges from the studies of embryonic tissues and stem cell-derived cardiomyocytes is that IP 3 Rs are expressed in cardiac precursor cells, and are relatively abundant at the very earliest stages of heart development when they may play a critical role in development. Their expression declines as the cells differentiate and other Ca 2+ -handling systems are put into place. However, IP 3 Rs are not completely lost. They are retained in the heart for the duration of fetal development and can be readily demonstrated in neonatal cardiac myocytes, and their expression persists into adulthood.
It should be noted that mice deficient in cardiac expression of type 2 IP 3 Rs are viable and do not have any apparent cardiac defects [17] . Furthermore, complete single deletion of type 1, type 2 or type 3 IP 3 Rs in mice, or combined knockout of types 2 and 3 IP 3 Rs, does not prevent the murine heart (or whole animal) from developing [110, 111] . These data could indicate that IP 3 Rs are not essential for cardiogenesis. However, it is possible that there is functional redundancy between IP 3 R isoforms, such that the presence of any one of the three isoforms will do. Alternatively, another Ca 2+ signaling mechanism could compensate for the normally undertaken by IP 3 Rs. Although knockout of types 2 and 3 IP 3 Rs appears to be benign, mice not expressing type 1 IP 3 Rs mostly die in utero [110] . It would be interesting to know if a lack of cardiac development was partially responsible for the increased mortality of these animals.
IP 3 signaling in atrial myocytes
There is substantial evidence for IP 3 Early evidence for an involvement of IP 3 in the regulation of atrial contraction came from the observation that phosphoinositide breakdown and inositol phosphate generation were accompanied by a positive inotropic effect [114] [115] [116] [117] [119] [120] [121] . Direct application of IP 3 to permeabilized atrial muscle [50] , photorelease of IP 3 [126] and, more recently, exposure of isolated atrial myocytes to a membrane permeable analogue of IP 3 [58, 63, 127, 128] provided definitive proof that IP 3 induces a positive inotropic effect in atrium. Thus, an important action of IP 3 in atrium is to increase the force of contraction.
Interestingly, receptor-mediated inositol phosphate production and expression of IP 3 Rs are larger in atrium than in ventricle [10, 17, 41, 58, 113] . For example, maximal muscarinic receptor-mediated inositol phosphate accumulation was N12-fold in guinea-pig atrial myocytes but only 7-fold in ventricular myocytes [10] . Similarly, in cat myocardium, muscarinic receptor stimulation induced larger increases in phosphatidylinositol breakdown in atria than in ventricles [113] . In rat and rabbit myocytes, expression of IP 3 Rs is~3.5-10 times larger in atrial as compared to ventricular myocytes [41, 58] . Microsomal preparations from human and sheep atrium displayed RyR densities of~0.3-0.7 pmol/mg protein [129, 130] . In contrast, IP 3 R density amounted to 1.8 pmol/mg protein in rat atrium [58] . Thus, atrial SR contains more IP 3 Rs, but less RyRs, than ventricular SR, suggesting that SR Ca 2+ release in atrial myocytes is more dependent on IP 3 signaling than in ventricular myocytes. In line with this notion, direct application of IP 3 to permeabilized rat myocytes revealed a~5 times larger global Ca 2+ increase in atrial than in ventricular myocytes [58] . Taken together, these data might explain, at least in part, why many transmitters and hormones coupling to the PIP 2 -PLC-IP 3 cascade exert comparatively large positive inotropic effects in the atrium but only small or no positive inotropic effects in the ventricle (e.g. angiotensin II [131] or 5-hydroxytryptamine [124] 3 Rs are distributed not only in the subsarcolemmal/ cytoplasmic compartment of atrial cells, but also in the perinuclear area, giving rise to the notion that they might control nuclear Ca 2+ . Direct functional evidence for this has been obtained recently in cat, rabbit and rat atrial myocytes [71, 72, 137] . In permeabilized cat atrial myocytes (Fig. 3A) , IP 3 or adenophostin elicited increases in nuclear Ca 2+ that could be blocked by IP 3 R antagonists [137] . In isolated nuclei (from whole hearts, Fig. 3B ), this IP 3 -induced Ca 2+ release was observed both at the outer and inner face of the nuclei suggesting that functional IP 3 Rs may be expressed at the outer and inner sides of the nuclear envelope facing the cytoplasm and the nucleoplasm, respectively [137] . Conversely, when the nuclear envelope was loaded with the low affinity Ca 2+ dye fluo-5N to measure nuclear envelope Ca 2+ concentration directly (Fig. 3C) , IP 3 reduced the Ca 2+ stored in the nuclear envelope [137] . Consistent with these findings from permeabilized myocytes and isolated nuclei, in electrically stimulated intact atrial myocytes, endothelin-1 augmented nuclear Ca 2+ transients through IP 3 signaling beyond the increase seen in the cytoplasm [71, 72] . At threshold concentrations, endothelin-1 even induced a selective increase in nuclear Ca 2+ transients [72] .
Collectively, these data show that in atrium IP 3 may not only increase contractility via elevated Ca 2+ transients, but that it also may induce arrhythmias and alter nuclear Ca 2+ signaling to promote remodeling and regulate excitation-transcription coupling. Thus, it appears as if the adverse actions of atrial IP 3 signaling outweigh the beneficial effects. Clearly, further work is required to define more precisely the physiological and pathological roles of IP 3 signaling in atrial myocardium.
IP 3 signaling in ventricular myocytes
There is abundant evidence that IP 3 Rs are expressed in mammalian ventricular myocytes [19, 58, 138] . IP 3 R expression has been qualified using real-time PCR [58] , Northern blotting [19, 91] , Western blotting [17, 41, 58] , immunofluorescence [18, 41, 139] and IP 3 binding [58, 139] . A number of studies have shown that ventricular myocyte IP 3 Rs are functional and have access to replete Ca 2+ stores in situ. For example, IP 3 has been shown to directly release Ca 2+ from permeabilized/ fractionated ventricular cells [41, 140, 141] . In addition, IP 3 Rs have been purified from ventricular myocytes, incorporated into lipid membranes and shown to open after addition of IP 3 [57] . Although published data have suggested that all three IP 3 R isoforms are expressed in ventricular myocytes, the majority of recent reports concur that type 2 IP 3 Rs constitute the predominant channel isoform [17, 18, 41, 58] .
Despite the numerous lines of evidence for their expression and activity, the functional roles of ventricular IP 3 [17, 41, 58] , and it is generally estimated that IP 3 Rs are outnumbered by RyRs by a ratio of~100:1.
The most obvious function for IP 3 Rs would be to act as an inotropic support for the ventricles by boosting the amplitude of systolic Ca 2+ transients, and thereby increasing contractile force. Consistent with this notion, IP 3 Rs have been localized close to the dyadic junctions where excitation-contraction coupling is initiated [142] , and direct activation of IP 3 Rs was found to enhance Ca 2+ spark occurrence throughout ventricular cells [41] . Furthermore, application of hormones that activate the production of IP 3 inside ventricular myocytes, such as endothelin-1 [11] , enhances systolic Ca 2+ signals in rat and rabbit cells [41, 128, 143] . IP 3 can therefore be considered as a bona fide inotropic agent in some mammalian ventricular myocytes (but perhaps not all; see [41] ). However, while positive inotropy is a beneficial effect of IP 3 R activation, the situation is not that straightforward. Rather than reinforcing their positive contribution to inotropy, the overwhelming majority of studies that have examined the consequence of activating IP 3 Rs in ventricular myocytes have concluded that the predominant effect is to stimulate arrhythmias [62, 143] . Indeed, IP 3 R activity has been suggested to underlie ventricular arrhythmias resulting from hormonal stimulation [143] , reperfusion [144, 145] , engagement of cytotoxic T-lymphocytes [146] and FAS receptor activation [147] . These data suggest that Ca 2+ flux through the relatively few IP 3 Rs in ventricular myocytes is perhaps more dangerous than beneficial, similar to the situation discussed above for atrial cells. 2+ increase is larger in the nucleus (black) than in the adjacent cytoplasm (red). (C) Confocal images of an isolated rat cardiac nucleus. The nuclear envelope (NE) has been loaded with the low affinity Ca 2+ dye fluo-5N. Addition of IP 3 causes a reduction of Ca 2+ stored in the NE. The Ca 2+ ionophore A23187 further depletes NE Ca 2+ . Modified from [137] . Copyright of the Journal of Physiology; used by kind permission.
An intriguing clue to another possibly significant physiological/pathological function of IP 3 Rs in ventricular myocytes is their localization close to the nucleus. A substantial proportion of IP 3 Rs in adult ventricular cells is expressed on unspecified membranes close to the nucleus, or indeed on the nuclear envelope [18, 148] . Furthermore, it has been shown that IP 3 can release Ca 2+ from the ventricular myocyte nuclear envelope (and also probably from adjacent connected membrane compartments) [140, 141] . This strategic positioning of a population of nucleus-associated IP 3 Rs potentially allows the generation of autonomous nuclear Ca 2+ signals, which may have a significant role in regulating cardiac gene transcription, and plausibly controlling processes such as cardiac hypertrophy. Indeed, it has been demonstrated that the release of perinuclear IP 3 -sensitive Ca 2+ stores promotes a CaMKII-dependent phosphorylation of histone deacetylase 5 (HDAC5) thereby causing it to be exported out of the nucleus [140] . Thus, perinuclear IP 3 -evoked Ca 2+ signals can derepress the expression of genes that underlie hypertrophic growth, such as those under the control of MEF2c [149] . It is well known that stimulation of myocytes with hormones that activate IP 3 production, e.g. ET-1, can promote hypertrophy [150] [151] [152] [153] [154] . What is not fully understood, however, is how such hormones can affect subtle changes in Ca 2+ -dependent gene transcription inside cells that experience periodic surges of Ca 2+ during excitation-contraction coupling [155] . Perinuclear IP 3 Rs may provide a resolution to this conundrum by providing a source of Ca 2+ signals that can be spatially and temporally dissociated from those that regulate contraction [156] . Consistent with this model, it has been demonstrated that activation of IP 3 Rs in rat neonatal ventricular myocytes using a membrane-permeant IP 3 analogue or an α 1 -adrenergic agonist causes perinuclear Ca 2+ release events, and that blocking IP 3 R opening decreases hypertrophic growth in response to phenylephrine stimulation [109] . Similar findings were made using mouse neonatal cells stimulated with ET-1 and phenylephrine; nuclear-associated IP 3 Rs triggered nucleoplasmic Ca 2+ signals and hypertrophic gene transcription [157] . Further work is required to establish whether this scheme is relevant in vivo. However, the concept that IP 3 Rs impact specifically on nuclear Ca 2+ signaling is gaining momentum. Numerous recent reports examining Ca 2+ signaling in neonatal [103, 108, 109, 157] , atrial [71, 72, 137] and ventricular myocytes [140] have demonstrated specific effects of IP 3 -generating agonists or IP 3 itself on nucleoplasmic Ca 2+ signals. Coupling these data with the observations that IP 3 is necessary for some forms of hypertrophy [109, 157, 158] raises the possibility that IP 3 Rs are key regulators of cardiac myocyte gene transcription and fate.
IP 3 Rs in other cardiac cells
The majority of studies examining cardiac IP 3 R expression and function have focused on developing embryonic/neonatal cells, or adult atrial and ventricular myocytes. However, there are reports suggesting that IP 3 Rs are also expressed in other cardiac regions/cell types, such as papillary muscle [48, 159] . It has also been proposed that IP 3 Rs are functional in nodal cells within the developing atria. Isolation of atrial cells from E14.5 mouse embryos revealed a minor population of spontaneously active myocytes (presumed to be pacemaking cells). Transfection of an enzyme that metabolizes IP 3 , and thereby prevents its Ca 2+ -mobilising action, or an anti-IP 3 R antibody, inhibited the spontaneous activity [97] . In the sinus node of the adult mammalian heart, spontaneously active pacemaker cells make use of cyclic subsarcolemmal RyR-mediated SR Ca 2+ release to activate depolarizing NCX current, which contributes to diastolic depolarization and pacemaker activity (for review see [160] ). This 'intracellular Ca 2+ clock' is fueled by high, cAMP-dependent Ca 2+ turnover. Increases and decreases, respectively, in intracellular cAMP levels modulate cycle length, i.e. heart rate, in part by alterations in PKA-dependent phosphorylation of phospholamban (and hence SR Ca 2+ load and release). Because of this Ca 2+ dependence of pacemaker activity, it appears feasible that IP 3 R-mediated SR Ca 2+ release might also modulate pacemaker activity in myocytes from adult sinus node. Direct evidence for an involvement of IP 3 signaling in the regulation of heart rate, however, is lacking. Angiotensin II and endothelin-1 (depending on species and experimental conditions), which are known to increase IP 3 in supraventricular tissue, exert positive chronotropic effects in mammalian heart via activation of AT 1 and ET B receptors, respectively (e.g. [161, 162] ). Whether PLC-IP 3 signaling is involved in the positive chronotropic effects of angiotensin II and endothelin-1 is not known at present. Evidence from amphibian sinus venosus, however, suggests that PLC-IP 3 signaling and IP 3 R-mediated SR Ca 2+ release depolarize the membrane potential of pacemaker cells thereby increasing heart rate [163] .
Purkinje cells also express IP 3 Rs [164] , seemingly to a greater extent than either atrial or ventricular myocytes [16] . The physiological function of IP 3 Rs in these cells is unclear, but they may plausibly underlie the increased automaticity of Purkinje fibers during adrenergic stimulation [165] or following infarct [166] . Purkinje cells from infarcted hearts show proarrhythmic propagating Ca 2+ waves that are reduced in frequency and amplitude by 2-APB. Also consistent with the notion of IP 3 Rs regulating automaticity of Purkinje fibers, reduction of IP 3 production using a phospholipase C inhibitor was demonstrated to inhibit their autonomous Ca 2+ spiking [102] .
An overview on the expression of IP 3 R isoforms in various regions of adult myocardium and the involvement of IP 3 signaling in excitation-contraction coupling, excitation-transcription coupling and arrhythmogenesis is provided in Table 1 and Fig. 4 , respectively. Table 1 also lists evidence in favor of altered IP 3 expression in various cardiac diseases (for a more detailed discussion on this issue see below). It should be noted that, unlike RyR2, IP 3 Rs are also expressed to a significant amount in non-myocytes in cardiac tissue (e.g. fibroblasts, endothelial and smooth muscle cells). Therefore, ideally expression of IP 3 Rs and alterations thereof in cardiac disease should be confirmed in cardiac myocytes. Otherwise, the possibility exists that the findings are obscured by IP 3 R expression from non-myocytes. For example, rat heart contains all three IP 3 R isoforms with the IP 3 R type 1 being the most abundant isoform (more than 60% of total IP 3 R mRNA). Ventricular myocytes, however, do not contain IP 3 R type 1 (less than 2% of total IP 3 R mRNA), but rather express the type 2 (85%) and 3 (14%) IP 3 R [57] . Thus, we have also indicated in Table 1 whether or not IP 3 R expression was confirmed in cardiac myocytes.
Is nuclear Ca
2+ regulated independently from cytoplasmic Ca 2+ ? Putative relevance of IP 3 -dependent nuclear Ca 2+ signaling for excitation-transcription coupling
As outlined above, there is clear evidence for regulation of nuclear Ca 2+ concentration by IP 3 signaling. The question arises, however, whether nuclear Ca 2+ in beating cardiomyocytes can be regulated independently from cytoplasmic Ca 2+ , which undergoes large changes (from~100 nM in diastole to N 1 μM in systole) during each heartbeat. The nuclear pores, which traverse the nuclear envelope, represent a direct connection between cytoplasm and nucleoplasm through which Ca 2+ can permeate. Consequently, increases in cytoplasmic Ca 2+ during systole also result in increases in nuclear Ca 2+ (see pathway #1 in Fig. 4 ). Due to a diffusional delay, the nuclear Ca 2+ transient lags behind the cytoplasmic Ca 2+ transient, as visualized by confocal Ca 2+ imaging [71, 72, 167] . Hormone-independent increases in cytoplasmic Ca 2+ transients (elicited by elevation of extracellular Ca 2+ ) are followed by increases in nuclear Ca 2+ transients of similar magnitude [72] . Thus, cytoplasmic Ca 2+ is an important determinant of nuclear Ca 2+ arguing that nuclear Ca 2+ in cardiac myocytes cannot be regulated entirely independently from cytoplasmic Ca 2+ . IP 3 signaling, however, is able to alter nuclear Ca 2+ selectively (see pathway #2 in Fig. 4) . IP 3 can release Ca 2+ from the nuclear envelope directly into the nucleoplasm through activation of IP 3 Rs located at the inner face of the nuclear envelope [137] . This IP 3 -induced Ca 2+ release into the nucleus may be very local [140] . It can cause selective increases in the nuclear Ca 2+ transient [72] , as illustrated in Fig. 5 , and activate nuclear CaMKIIδ B to promote phosphorylation of HDACs and, thereby, transcription [140] . In this way, IP 3 can regulate nuclear Ca 2+ -dependent processes like transcription independently from 12. Pathological relevance of IP 3 signaling IP 3 -induced Ca 2+ release from the SR and the nuclear envelope may initiate arrhythmias and alter gene expression to induce hypertrophy and heart failure, as discussed above. In line with this notion, many signaling systems, most notably the sympathetic, the renin-angiotensin and the endothelin system, are activated during cardiac diseases associated with arrhythmias, hypertrophy and heart failure along with alterations in the expression of cardiac IP 3 Rs. Substantive evidence suggests that IP 3 signaling may be involved in the development and/or maintenance of atrial fibrillation, reperfusion arrhythmias, ankyrin-B-related arrhythmias, diabetic cardiomyopathy, hypertrophy and heart failure.
Atrial fibrillation
Atrial fibrillation (AF) is the most common arrhythmia. Its incidence increases with age, as does the expression of the IP 3 R in the heart [168] . Expression of the IP 3 R is augmented in a dog model of AF and in human AF [15, 169, 170] . Furthermore, cardiac tissue levels of endothelin and angiotensin II are elevated in cardiac diseases associated with AF. Both endothelin and angiotensin II increase IP 3 generation [122, 123] and elicit arrhythmias in isolated human atrial myocardium [134, 135] .
Thus, endothelin-and angiotensin II-induced IP 3 signaling may be involved in the initiation and progression of AF. While endothelin receptor antagonists have not yet been tested for their therapeutic potential against AF, several recent clinical trials suggest that ACE inhibition and AT 1 receptor blockade reduce the incidence of AF in patients at risk of developing the arrhythmia (reviewed in [171] ). Furthermore, mutations in the adaptor protein ankyrin-B, which is required for post-translational stability and SR targeting of IP 3 Rs, are associated with AF (see below).
Reperfusion arrhythmias
Ischemia and reperfusion can cause arrhythmias and sudden cardiac death. Upon reperfusion after an ischemic insult, there is a surge of IP 3 concentration in cardiac myocytes. The transient increase in IP 3 concentration is the result of α 1 -adrenergic receptor stimulation by norepinephrine, which is released from sympathetic nerve endings within the heart. The increase in IP 3 concentration correlates with the induction of arrhythmias, ventricular tachycardia and ventricular fibrillation [145] . Substances able to inhibit the IP 3 increase prevent the arrhythmias [145, 172, 173] . Inhibition of the Na + /H + exchanger (NHE) and NCX is also effective against the development of the arrhythmias [174, 175] . This suggests that Na + influx through NHE, followed by Na + exit and Ca 2+ influx through reverse mode NCX leads to an increase in SR Ca 2+ load. IP 3 -induced SR Ca 2+ release with subsequent activation of forward mode NCX may then trigger the arrhythmias. Reperfusion-induced increase in IP 3 concentration has been observed in atria and ventricles from both rat and human hearts following stimulation with either norepinephrine or thrombin (e.g. [4, 173, 176, 177] ).
Arrhythmias related to ankyrin-B mutations
Ankyrin-B is a 220 kDa adaptor protein that directly interacts with the IP 3 R in cardiac myocytes. High affinity interaction between ankyrin-B and IP 3 R is required for post-translational stability and targeting of the IP 3 R to SR microdomains closely opposed to neighboring T tubules [178, 179] . Loss-of-function mutations in ankyrin-B cause reduction of IP 3 Rs in specialized SR-T tubule junctions (distinct from the classical dyads) in cardiac myocytes and are associated with arrhythmias ranging from bradycardia, sinus arrhythmia, atrial fibrillation and catecholaminergic polymorphic ventricular tachycardia to ventricular fibrillation both in humans and in mice heterozygous for a null mutation in ankyrin-B (ankyrin-B +/− mice) [142, 180] . In patients affected by ankyrin-B mutations, emotional or physical stress may lead to syncopes and sudden death. The cellular mechanisms underlying the ankyrin-B-related arrhythmias may involve altered Na + and Ca 2+ homeostasis. The macromolecular complex in the SR-T tubule junctions is composed of ankyrin-B, IP 3 
Diabetic cardiomyopathy
Diabetic cardiomyopathy is now recognized as a distinct clinical entity with characteristic structural and functional changes of the heart. Ca 2+ homeostasis is altered in myocytes from diabetic hearts such that electrically stimulated Ca 2+ transients are reduced and prolonged. These alterations are the result of changes in the expression and function of SR Ca 2+ handling proteins; SERCA2a, NCX and RyR expressions are reduced, whereas phospholamban expression is increased and its phosphorylation decreased. As a consequence, SR Ca 2+ load is reduced, and SR Ca 2+ release and re-uptake are impaired [181, 182] . Interestingly, an increased propensity toward arrhythmogenic afterdepolarizations has been observed in diabetic cardiomyocytes [182] . Insulin increases IP 3 concentration and triggers arrhythmic Ca 2+ release events in myocytes from diabetic ob/ob mice -but not from wild-type mice -and this effect is mediated via IP 3 signaling [183] . IP 3 R expression (type 1 and type 2 IP 3 Rs) is unaltered in ventricles from ob/ob mice [183] , but decreased in a diabetes model in the rat and in atrium from diabetic patients [184, 185] . Both increased and decreased IP 3 production in response to α-adrenergic stimulation has been reported in diabetes [186, 187] . PIP 2 levels and the expression and activities of PLC isoenzymes are reduced [188] . Taken together, these data indicate that altered receptor-PLC coupling, IP 3 generation and IP 3 -induced SR Ca 2+ release may contribute to impaired Ca 2+ handling and arrhythmogenesis in diabetic cardiomyopathy.
Hypertrophy and heart failure
Many agonists of G q protein-coupled receptors induce cardiac hypertrophy that eventually may deteriorate into heart failure. The best studied and, possibly, clinically most relevant examples include angiotensin II, endothelin-1 and norepinephrine acting predominantly via AT 1 , ET A and α 1 -adrenergic receptors, respectively. Plasma and tissue levels of angiotensin II, endothelin-1 and norepinephrine and receptor densities are often increased in hypertrophy. However, a direct role for IP 3 signaling in cardiac hypertrophy has remained elusive until most recently, since the respective receptors couple to various signaling pathways each of which may culminate into hypertrophy.
Early evidence suggested that IP 3 signaling in hypertrophy may be unaltered or even impaired [189, 190] . More recent studies, however, collectively point toward an important role of PLC-IP 3 signaling in the development and progression of hypertrophy. For example, in pressure overload-induced hypertrophy, PLC activity was elevated and norepinephrineinduced generation of IP 3 was increased [191] . Moreover, IP 3 -induced Ca 2+ release from the SR was larger in myocytes from hypertensive rats than from control rats [192] . In volume overload-induced hypertrophy, sarcolemmal PIP 2 levels were decreased, whereas PLCβ1 and PLCγ1 expression and activities and IP 3 levels were increased [193] . Furthermore, in hypertrophy induced by transient overexpression of a constitutively active G qα , PLCβ1 and PLCβ3 expressions were elevated [194] . Thus, PLC-IP 3 signaling and IP 3 -induced Ca 2+ release are enhanced in cardiac hypertrophy. These findings also provide an explanation for the progressive nature of cardiac hypertrophy: initiation of increased gene expression through nuclear IP 3 -induced Ca 2+ release appears to contribute to increased expression of the very machinery responsible for the generation of IP 3 , thereby creating a positive feedback loop [195] .
Heart failure is accompanied by neurohormonal activation, including the sympathetic nervous system, the renin-angiotensin system and the endothelin system. Cardiac tissue levels of norepinephrine, angiotensin II and endothelin are elevated. Expression of the respective receptors (which couple to IP 3 formation) is altered. In human heart failure, expression of α 1 -adrenergic receptors is unchanged (but their relative expression is increased due to a large downregulation of the predominating β 1 -adrenergic receptors) [196] , AT 1 receptors are downregulated (presumably due to increased angiotensin II levels [197] ) and ET A receptors are upregulated [198, 199] . In animal models of heart failure, changes in phosphoinositide metabolism occur, including alterations in the abundance, expression and/or activity of PIP 2 , PI-4 kinase, PIP-5 kinase, PLC isoforms and inositol phosphates [200, 201] . Expression of IP 3 Rs is increased in both human and animal heart failure, whereas RyR levels are reduced, indicating a shift toward more IP 3 R-mediated Ca 2+ release in the failing heart [19, 202] . These data indicate that, in heart failure, there are complex changes in the transmitter and receptor systems coupling to IP 3 formation as well as in the regulation of IP 3 Rs suggesting that IP 3 -induced Ca 2+ release is involved in the development and/or progression of the disease.
Unresolved questions and future perspectives
Recent years have seen tremendous advances in our understanding of IP 3 signaling in cardiac myocytes. There is no longer any doubt that IP 3 plays important physiological and pathological roles in the heart. These roles, however, are incompletely understood and remain to be defined more precisely. A puzzling aspect of IP 3 signaling in adult cardiac myocytes is that apparently it exerts more adverse than beneficial effects. Is IP 3 signaling in adult myocardium a mere remnant of the developing heart or does it serve unique functions beyond arrhythmogenesis and induction of (maladaptive) remodeling? Further important but still largely unresolved questions are: Why do cardiac myocytes express different IP 3 R isoforms? How is expression of IP 3 Rs regulated? What is the composition, subcellular distribution and functional role of IP 3 R macromolecular complexes in cardiac myocytes? Which kinases and phosphatases regulate cardiac IP 3 R phosphorylation and what is the functional impact of this regulation? By what other means is IP 3 R function regulated? How exactly is IP 3 signaling involved in the development and progression of cardiac diseases? Future studies should aim at answering these questions. Clearly, IP 3 signaling in cardiac myocytes will continue being an important topic in cardiac physiology as well as cardiology. It certainly holds the promise for further surprises and excitement.
